Clicky

CSPC Pharmaceutical Group Ltd(1093)

Description: CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.


Keywords: Medicine Pharmaceutical Products Pain Diabetes Antibiotics Breast Cancer Infection Chemotherapy Healthcare Service Hypertension Arthritis Lymphoma Osteoporosis Osteoarthritis Multiple Myeloma Functional Food Spondylitis Back Pain Ankylosing Spondylitis Malignant Tumors Upper Respiratory Tract Infection Strain Soft Tissue Injuries Acute Ischemic Stroke Human Back Shijiazhuang Pharma Group Low Back Pain

Home Page: www.cspc.com.hk

No. 226 Huanghe Street
Shijiazhuang, 050035
China
Phone: 86 31 1870 37015


Officers

Name Title
Mr. Dongchen Cai Exec. Chairman
Mr. Cuilong Zhang Vice-Chairman & CEO
Mr. Chunlei Li Exec. Director & Chief Scientist
Mr. Kin Man Chak Exec. Director
Mr. Weidong Pan Exec. Director
Mr. Huaiyu Wang Exec. Director
Mr. Zhenguo Wang Exec. Director
Dr. Qingxi Wang Exec. Director
Dr. Hao Jiang Exec. Director
Mr. Jinxu Wang Sr. VP

Exchange: HK

Country: HK

Currency: Hong Kong Dollar (HK$)

Forward PE: 13.7174
Trailing PE: 17.3019
Price-to-Book MRQ: 3.2578
Price-to-Sales TTM: 3.3406
IPO Date: 1994-06-21
Fiscal Year End: December
Full Time Employees: 24746
Back to stocks